A blog about chemistry, drug development, science, and technology
Ranbaxy seems to be acquiring companies world-wide. Now they are purchasing a Russian generic drug manufacturer, Akrikhin for a reported $100 million.
‘Ranbaxy close to $100mn Russian buy’:
Akrikhin has a website but unfortunately it is only in Russian. Ranbaxy won’t comment on the reported purchase but they did state they are looking at acquisitions. They have purchased the following companies in the past five months:
• Allen SpA (formerly division of GlaxoSmithKline) in Italy; March 2006 for undisclosed amount
• Terapia in Romania March 2006 for $324 million
• Mundogen (formerly division of GlaxoSmithKline) in Spain; July 2006 for undisclosed amount
• Ethimed in Belgium; March 2006 for an undisclosed amount
Here are articles on these acquisitions.
The Telegraph - Calcutta : Business
Ranbaxy Acquires Leading Romanian Pharma Company Terapia for US $324mn
Ranbaxy Pharmaceuticals Inc. To Acquire The Mundogen Generic
Ranbaxy acquires Belgian generics company - Pharmaceutical Business Review
I think Ranbaxy is already well on its way to becoming one of the top world-wide generic manufacturers. The challenge will be how to develop and instill a corporate culture in light of the rapid expansions into many different cultures. It will be interesting to see how well they integrate these companies into their current operations.
Technorati Tags: pharma M&A, Ranbaxy
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 1.259 seconds